LCA and RP patients show functional improvements with oral synthetic retinoid

Arthur Cummings
Published: Tuesday, May 5, 2015
Repeat courses of treatment with oral 9-cis-retinyl acetate (QLT091001, QLT Inc) in patients with Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) due to genetic mutations in RPE65 or LRAT had an acceptable safety profile and led to sustained visual improvements, according to the results of RET IRD 02, a multicenter Phase 1b study.
The findings were presented by Hendrik P. Scholl, MD, MA, at the Association for Research in Vision and Ophthalmology annual meeting.
The study enrolled patients treated with a single 7-day course of QLT091001 10 or 40 mg/m2 in an earlier study. In RET IRD 02, patients received up to 3 7-day courses of the oral synthetic cis-retinoid at doses of 10, 40, or 60 mg/m2.
Ten (77%) of 13 LCA patients and 12 (86%) of 14 RP patients were “responders” (met threshold criteria for improvement) in at least 1 eye in either functional retinal area (Goldmann visual field) or ETDRS visual acuity.
Most adverse events were mild (78%) or moderate (18%) in intensity, consistent with the retinoid class, and transient and/or reversible, reported Dr. Scholl, The Dr. Frieda Derdeyn Bambas Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD.
“We must be cautious because this is not placebo-controlled study. However, these are diseases where patients decline over time and never get better. So, when you see any improvement, it is quite a surprise,” he said.
Latest Articles
ESCRS Today 2025: Happy Anniversaries!
ESCRS celebrates milestones with pioneers in IOLs, LASIK, femtosecond lasers, and corneal transplantation.
ESCRS Today 2025: A Congress for Everyone
From YOs to families, the ESCRS Annual Meeting embraces full participation through inclusivity.
Beyond the Numbers
Empowering patient participation fosters continuous innovation in cataract surgery.
Thinking Beyond the Surgery Room
Practice management workshop focuses on financial operations and AI business applications.
Aid Cuts Threaten Global Eye Care Progress
USAID closure leads retreat in development assistance.
Supplement: ESCRS Clinical Trends Series: Presbyopia
Debate: FS-LASIK or KLEx for Hyperopia?
FS-LASIK has more of a track record, but KLEx offers advantages.
Four AI Applications Ready for Practice
Commercial offerings may save time, improve practice and research.
Perioperative Medication Regimens for Cataract Surgery
Randomised controlled clinical trial results provide evidence-based guidance.